Login / Signup

Editorial Comment to Resumption of anti-programmed cell death 1 monotherapy for severe immune-related adverse events experienced patient with renal cell carcinoma.

Ario TakeuchiMasaki Shiota
Published in: IJU case reports (2020)
Keyphrases
  • editorial comment
  • renal cell carcinoma
  • case report
  • combination therapy
  • early onset
  • open label
  • drug induced
  • randomized controlled trial
  • clinical trial
  • double blind